Touting pricetag, Mylan launches Advair generic

Mylan (NSDQ:MYL) today announced the launch of its Wixela Inhub product, a generic for GlaxoSmithKline‘s (NYSE:GSK) Advair Diskus device, for people with asthma or chronic obstructive pulmonary disease.

The company touted that its device’s list price is 70% less than Advair Diskus and 67% less than GSK’s generic.

The wholesale acquisition costs for Mylan’s Wixela Inhub devices are $93.71 for the 100mcg/50mcg strength, $116.44 for the 250mcg/50mcg strength and $153.14 for the 500mcg/50mcg strength.

“We’ve had numerous discussions with customers about the need for a unique launch strategy for the first substitutable generic of Advair Diskus that increases affordability to all in our healthcare system,” chief commercial officer Tony Mauro said in prepared remarks.

“We trust that by launching Wixela Inhub at a significantly discounted list price, we will demonstrate the savings that generics can deliver for patients through reduced out-of-pocket costs, as well as the U.S. healthcare system overall,” Mauro added.

Mylan won FDA approval for the Advair generic in January.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW